HCW Biologics Advances Second-Generation Immunotherapeutics With TGF-ß/IL-15 Fusion

HCW Biologics Inc. (HCWB) reported new findings supporting its TGF-β trap and IL-15 fusion platform as a potential immunotherapy across cancer and autoimmune/senescence-associated diseases. The update is product/clinical-science oriented but does not include quantified efficacy or regulatory milestones in the provided text. Overall, this modestly improves the development narrative without indicating near-term commercialization impact.